BioMD Genetics Inc.

biomdgenetics.com

BioMD Genetics Inc. is a Canadian innovation-driven company that provides human genetic testing solutions to business partners AND personal genetics service directly to consumers and through authorized retailers. We have been constantly innovating and using the best current practices and technologies of human genetics science to provide our clients and customers with the best possible experience. Our highly creative and qualified team, consisting of researchers, practitioners and bioinformatics, ensures that top-quality services are delivered to our clients and customers.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

BRAZIL’S SENAI CIMATEC DOSES FIRST HEALTHY VOLUNTEERS IN PHASE 1 TRIAL OF HDT BIO’S RNA COVID-19 VACCINE

HDT Bio Corp. | January 17, 2022

news image

HDT Bio Corp., a U.S. developer of immunotherapies for oncology and infectious diseases and SENAI CIMATEC, an important Brazilian education, research, and innovation institute, have dosed the first healthy volunteers in Brazil in a Phase 1 trial of HDT Bio’s RNA COVID-19 vaccine, HDT-301. SENAI CIMATEC will conduct the clinical trial under the name Vaccine RNA MCTI-CIMATEC-HDT. The vaccine uses HDT Bio’s proprietary lipid nanoparticle RNA-delivery technology. Read More

Diagnostics

VERISIM LIFE AND TOTAL BRAIN ANNOUNCE STRATEGIC COLLABORATION AGREEMENT APPLYING AI TO DEVELOP NEW DRUGS FOR NEUROLOGICAL DISORDERS

VeriSIM Life | May 30, 2022

news image

VeriSIM Life (VeriSIM), the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced that it has entered into a partnership agreement with Total Brain www.totalbrain.com, an applied, integrative neuroscience company, to create breakthrough neurodata-driven actionable insights for developing novel drugs to treat a wide range of neurological disorders. The partnership will pioneer the integration of Total Bra...

Read More

ALLIGATOR BIOSCIENCE PRESENTS POSITIVE BIOMARKER DATA DEMONSTRATING PROOF OF MECHANISM IN MITAZALIMAB CLINICAL PHASE I STUDY

PR Newswir | September 04, 2020

news image

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today biomarker data from a recently performed clinical Phase I study of the drug candidate mitazalimab, its wholly owned CD40 antibody in development primarily for the treatment of pancreatic cancer. The data will be presented today at the scientific conference PEGS: The Essential Protein Engineering Summit being held virtually August 31- September 4, 2020."The presented biomarker data confirm the proof of mechanism and strengt...

Read More

Industrial Impact

GINKGO BIOWORKS AND THE RWANDA DEVELOPMENT BOARD ANNOUNCE PLANS TO DEVELOP AND IMPLEMENT NEW BIOSECURITY CAPABILITIES IN RWANDA

Ginkgo Bioworks | August 12, 2022

news image

Ginkgo Bioworks the leading horizontal platform for cell programming, and the Rwanda Development Board representing the government of the Republic of Rwanda, today announced that they have entered into a Memorandum of Understanding with the intent of developing and implementing new biosecurity capabilities in Rwanda. The initial goal of the planned partnership is to support Rwanda's public health institutions as they work to address biosecurity challenges in the region. ...

Read More
news image

Cell and Gene Therapy

BRAZIL’S SENAI CIMATEC DOSES FIRST HEALTHY VOLUNTEERS IN PHASE 1 TRIAL OF HDT BIO’S RNA COVID-19 VACCINE

HDT Bio Corp. | January 17, 2022

HDT Bio Corp., a U.S. developer of immunotherapies for oncology and infectious diseases and SENAI CIMATEC, an important Brazilian education, research, and innovation institute, have dosed the first healthy volunteers in Brazil in a Phase 1 trial of HDT Bio’s RNA COVID-19 vaccine, HDT-301. SENAI CIMATEC will conduct the clinical trial under the name Vaccine RNA MCTI-CIMATEC-HDT. The vaccine uses HDT Bio’s proprietary lipid nanoparticle RNA-delivery technology. Read More

news image

Diagnostics

VERISIM LIFE AND TOTAL BRAIN ANNOUNCE STRATEGIC COLLABORATION AGREEMENT APPLYING AI TO DEVELOP NEW DRUGS FOR NEUROLOGICAL DISORDERS

VeriSIM Life | May 30, 2022

VeriSIM Life (VeriSIM), the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced that it has entered into a partnership agreement with Total Brain www.totalbrain.com, an applied, integrative neuroscience company, to create breakthrough neurodata-driven actionable insights for developing novel drugs to treat a wide range of neurological disorders. The partnership will pioneer the integration of Total Bra...

Read More
news image

ALLIGATOR BIOSCIENCE PRESENTS POSITIVE BIOMARKER DATA DEMONSTRATING PROOF OF MECHANISM IN MITAZALIMAB CLINICAL PHASE I STUDY

PR Newswir | September 04, 2020

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today biomarker data from a recently performed clinical Phase I study of the drug candidate mitazalimab, its wholly owned CD40 antibody in development primarily for the treatment of pancreatic cancer. The data will be presented today at the scientific conference PEGS: The Essential Protein Engineering Summit being held virtually August 31- September 4, 2020."The presented biomarker data confirm the proof of mechanism and strengt...

Read More
news image

Industrial Impact

GINKGO BIOWORKS AND THE RWANDA DEVELOPMENT BOARD ANNOUNCE PLANS TO DEVELOP AND IMPLEMENT NEW BIOSECURITY CAPABILITIES IN RWANDA

Ginkgo Bioworks | August 12, 2022

Ginkgo Bioworks the leading horizontal platform for cell programming, and the Rwanda Development Board representing the government of the Republic of Rwanda, today announced that they have entered into a Memorandum of Understanding with the intent of developing and implementing new biosecurity capabilities in Rwanda. The initial goal of the planned partnership is to support Rwanda's public health institutions as they work to address biosecurity challenges in the region. ...

Read More

Resources

resource image

Cell and Gene Therapy

VIA Thaw™ automated dry thawer

Video

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us